KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of EBT Margin data on record, last reported at 32.54% in Q4 2025.

  • For Q4 2025, EBT Margin rose 611.0% year-over-year to 32.54%; the TTM value through Dec 2025 reached 41.4%, up 3115.0%, while the annual FY2025 figure was 41.4%, 3115.0% up from the prior year.
  • EBT Margin reached 32.54% in Q4 2025 per RIGL's latest filing, down from 39.76% in the prior quarter.
  • Across five years, EBT Margin topped out at 58.99% in Q2 2025 and bottomed at 164.0% in Q1 2022.
  • Average EBT Margin over 5 years is 21.48%, with a median of 11.51% recorded in 2023.
  • The widest YoY moves for EBT Margin: up 11396bps in 2022, down -21494bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 111.23% in 2021, then soared by 102bps to 2.73% in 2022, then decreased by -25bps to 2.06% in 2023, then skyrocketed by 1184bps to 26.43% in 2024, then rose by 23bps to 32.54% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 32.54% in Q4 2025, 39.76% in Q3 2025, and 58.99% in Q2 2025.